Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer

NCT00183898 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
75
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Southern California

Collaborators